The role of photovaporization of the prostate in small volume benign prostatic hyperplasia and review of the literature

Abstract Objective Our objective was to characterize the safety and efficacy of the 180 W XPS-GreenLight laser in men with lower urinary tract symptoms secondary to a small volume benign prostatic hyperplasia (BPH). Methods A retrospective analysis was performed for all patients who underwent 180 W XPS-laser photovaporization of the prostate (PVP) vaporization of the prostate between 2012 and 2016 at two tertiary medical centers. Data collection included baseline comorbidities, disease-specific quality of life scores, maximum urinary flow rate (Q max ), postvoid residual (PVR), comorbidities, prostate volume and prostate-specific antigen (PSA). The secondary endpoints were the incidence of intraoperative and postoperative adverse events. Complications were stratified using the Clavien-Dindo grading system up to 90 days after surgery. Results Mean age of men was 67.8 years old, with a mean body mass index of 29.7 kg/m 2 . Mean prostate volume as measured by transrectal ultrasound was 29 mL. Anticoagulation use was 47% and urinary retention with catheter at time of surgery was 17%. Mean hospital stay and catheter time were 0.5 days. Median follow-up time was 6 months with the longest duration of follow-up being 22.5 months (interquartile range, 3–22.5). The International Prostate Symptom Score improved from 22.8 ± 7.0 at baseline to 10.7 ± 7.4 ( p p max improved from 7.70 ± 4.46 mL/s at baseline to 17.25 ± 9.30 mL/s ( p p p p p Conclusion The 180 W GreenLight XPS system is safe and effective for men with small volume BPH. PVP produced improvements in symptomatic and clinical parameters without any safety concern. It represents a safe surgical option in this under studied population.